Compare Incyte Corporation (INCY) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Nuscale Power Corporation — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Nuscale Power Corporation trades at $8.1 (market cap $2.76B). The key difference: Incyte Corporation is far larger — about 8.4× Nuscale Power Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | SMR | |
|---|---|---|
Market Cap | $23.11B | $2.76B |
Sector | Health | Utilities |
52-Week High | $118.52 | $53.43 |
52-Week Low | $67.38 | $7.64 |
Enterprise Value | $19.13B | $1.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company faces severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61M in 2025. Recent earnings misses and high cash burn highlight execution risks, yet analyst consensus suggests 54% upside to a $12.25 price target, with 50% of coverage rating the stock a Buy amid optimism for its small modular reactor technology.
The stock presents a high-risk, high-reward opportunity. Long-term potential hinges on commercializing its nuclear technology, but near-term risks include persistent losses, funding needs, and project delays. Investors must weigh the speculative growth narrative against fundamental weaknesses and high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
